Sarepta Therapeutics
SRPT
396 hedge funds and large institutions have $7.92B invested in Sarepta Therapeutics in 2023 Q4 according to their latest regulatory filings, with 75 funds opening new positions, 124 increasing their positions, 139 reducing their positions, and 66 closing their positions.
81% more call options, than puts
Call options by funds: $655M | Put options by funds: $362M
14% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 66
0% more funds holding
Funds holding: 395 → 396 (+1)
1.55% less ownership
Funds ownership: 89.26% → 87.71% (-1.6%)
11% less repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 139
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
21% less capital invested
Capital invested by funds: $10.1B → $7.92B (-$2.17B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$280M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$79.9M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$65.7M |
| 4 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$50.7M |
| 5 |
Morgan Stanley
New York
|
+$50.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$317M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$97.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$67.9M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
-$67.6M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$56M |
SRPT Hedge Fund Activity: Q4 2023 in Review
396 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q4 2023, worth a combined $7.92B — down 21% from $10.1B a quarter earlier.
Buyers outnumbered sellers: 75 funds opened new SRPT positions and 66 closed out — a net gain of 9 holders — while 124 added to existing stakes and 139 trimmed.
The largest buyer was Capital International Investors, adding an estimated $280M. The largest seller was JP Morgan Chase, cutting an estimated $317M.
- 396 institutional investors held Sarepta Therapeutics (SRPT) as of Q4 2023, up from 395 in Q3 2023.
- Funds reported $7.92B of Sarepta Therapeutics stock for Q4 2023, down 21% quarter-over-quarter.
- 75 funds opened new Sarepta Therapeutics positions in Q4 2023 and 66 closed out, a net change of +9 holders.
- The largest Sarepta Therapeutics buyer in Q4 2023 was Capital International Investors, an estimated $280M added.
- The largest Sarepta Therapeutics seller in Q4 2023 was JP Morgan Chase, an estimated $317M sold.
Based on aggregated 13F filings for Q4 2023.